Volume 10 Number 2 (April 2019)


Bioscience Discovery, 10(2):61-63, April - 2019

Prevalence of β-Lactamase Producing Carbapenem-Resistant Enterobacteriaceae among the Patients Attending Bharatpur Hospital

Sanjib Adhikari1, Sujan Khadka1*, Jid Chani Rana2, Sushmita Baniya1, Susma Poudel1, Archana Chapagain1 and Ramesh Regmi1

1Department of Microbiology, Birendra Multiple Campus, Tribhuvan University, Chitwan, Nepal.
2Research Laboratory, Bharatpur Hospital, Chitwan, Nepal.
*Sujan Khadka, Email: sukha11@yahoo.com

Article info
Received: 01-03-2019,
Revised: 04-04-2019,
Accepted: 10-04-2019

Abstract
Carbapenems are regarded as the last drugs of choice for the treatment of the infections caused by drug-resistant bacteria. The emergence of carbapenem-resistant Enterobacteriaceae (CRE) has become a major public health concern worldwide and a new challenge in the treatment of infectious diseases. The study was conducted to determine the prevalence of CRE at a tertiary care hospital in Bharatpur Chitwan, Nepal from September 2016 to February 2017. Aseptically collected clinical specimens (urine, pus, and blood) were cultured in Mac-Conkey agar and blood agar and the Gram-negative isolates obtained were subjected to an array of biochemical tests. Antibiotic Susceptibility Test (AST) was performed against carbapenem antibiotics for Enterobacteriaceae isolates by the disc-diffusion method according to CLSI (Clinical and Laboratory Standards Institute) guidelines.  Among 1720 samples, only 287 showed growth. Enterobacteriaceae isolates were recovered from 140 samples.  Carbapenem resistance in Klebsiella pneumoniae (57.1%) was higher than in E. coli (41.3%). Overall prevalence of CRE was 40.7%.  Among the CRE isolates, E. coli (78.9%) was more frequent than K. pneumoniae (21.0%). On phenotypic testing, the carbapenemase-producing bacteria were found to be K. pneumoniae (33.3%), Enterobacter aerogenes (33.3%) and E. coli (15.6%). Higher prevalence of carbapenem-resistant Enterobacteriaceae isolated from hospitalized and OPD-patients emphasize an urgent need for CRE control activities and rationalizing the use of antibiotics.

Keywords
Carbapenems, Carbapenem-resistant Enterobacteriaceae, Blood, Pus, Urine

REFRENCES
Bassetti M, Nicolini L, Esposito S, Righi E, Viscoli C. 2009. “Current Status of Newer Carbapenems.” Current Medicinal Chemistry 16 (5): 564–75.
Bhandari P, Thapa G, Pokhrel BM, Bhatta DR and Devkota U. 2015. “Nosocomial Isolates and Their Drug Resistant Pattern in ICU Patients at National Institute of Neurological and Allied Sciences, Nepal.” Int J Microbiol. doi:10.1155/2015/572163.
Bora A, Sanjana R, Jha BK, Mahaseth SN and Pokharel K. 2014. “Incidence of Metallo-Beta Lactamase Producing Clinical Isolates of Escherichia Coli and Klebsiella Pneumoniae in Central Nepal.” BMC Res Notes 7: 557.
Bratu S, Brooks S, Burney S, Kochar S, Gupta J, Landman D and Quale J. 2007. “Detection and Spread of Escherichia Coli Possessing the Plasmid-Borne Carbapenemase KPC-2 in Brooklyn, New York.” Clin Infect Dis. 44 (7): 972–75.
Bratu S, Landman D, Alam M, Tolentino E and Quale J. 2005. “Detection of KPC Carbapenem-Hydrolyzing Enzymes in Enterobacter Spp. from Brooklyn, New York.” Antimicrob Agents Chemother. 49 (2): 776–778. doi:10.1128/AAC.49.2.776-778.2005.
Brennan BM, Coyle JR, Marchaim D, Pogue JM, Boehme M, Finks J and Malani AN, et al. 2014. “Statewide Surveillance of Carbapenem-Resistant Enterobacteriaceae in Michigan.” Infect Control Hosp Epidemiol. 35 (4): 342–49.
Brenner DJ, Krieg NR, Staley JT, Garrity GM, Boone DR, Vos PD, Goodfellow M, Rainey FA and Schleifer KH. 2005. “The Proteobacteria, Part B. The Gammaproteobacteria.” In Bergey’s Manual of Systematic Bacteriology, 1203. Springer US. doi:https://doi.org/10.1007/0-387-28022-7.
Brink A, Coetzee J, Clay C, Corcoran C, van Greune J, Deetlefs JD, Nutt L, Feldman C, Richards G, Nordmann P and Poirel L. 2012. “The Spread of Carbapenem-Resistant Enterobacteriaceae in South Africa: Risk Factors for Acquisition and Prevention.” S Afr Med J. 102 (7): 599–601.
Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen Ø, Seifert H, Woodford N and Nordmann P. 2012.
“European Network on Carbapenemases: Rapid Evolution and Spread of Carbapenemases among Enterobacteriaceae in Europe.” Clin Microbiol Infect. 18 (5): 413–31.
CDC. 2009. “Centers for Diseases Control and Prevention. Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing Enterobacteriaceae in Acute Care Facilities.” MMWR Morb Mortal Wkly Rep. 58 (10): 256–60.
CDC. 2013. “Centers for Disease Control and Prevention: Vital Signs: Carbapenem-Resistant Enterobacteriaceae.” MMWR 62 (9): 165–70.
CLSI. 2011. “Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing. Twenty-First Informational Supplement. M100-S16 Wayne, PA” 31 (1): 1–165.
Cornaglia G, Guan L, Fontana R and Satta G. 1992. “Diffusion of Meropenem and Imipenem through the Outer Membrane of Escherichia Coli K-12 and Correlation with Their Antibacterial Activities.” Antimicrob Agents Chemother. 36 (9): 1902–8.
Forbes BA, Sahm DF and Weissfeld AS. 2007. Bailey and Scott’s Diagnostic Microbiology. 12 edition. Mosby.
Gupta N, Limbago BM, Patel JB and Kallen AJ. 2011. “Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention.” Clin Infect Dis. 53 (1): 60–67.
Hawkey PM. 2008. “The Growing Burden of Antimicrobial Resistance.” J Antimicrob Chemother. 62 (1): 1–9.
Jacoby GA, Mills DM and Chow N. 2004. “Role of Beta-Lactamases and Porins in Resistance to Ertapenem and Other Betalactams in Klebsiella Pneumoniae.” Antimicrob Agents Chemother. 48: 3203–6.
Jacoby JT, Klein GE, Laxminarayan R, Beldavs Z, Lynfield R, Kallen AJ and Ricks P, et al. 2013. “Vital Signs: Carbapenem-Resistant Enterobacteriaceae.” MMWR 62 (9): 165–69.
Karn S, Pant ND, Neupane S, Khatiwada S, Basnyat S and Shrestha B. 2016. “Prevalence of Carbapenem Resistant Bacterial Strains Isolated from Different Clinical Samples: Study from a Tertiary Care Hospital in Kathmandu, Nepal.” Journal of Biomedical Sciences 3 (1): 11–15.
Khanal S, Joshi DR, Bhatta DR, Devkota U and Pokhrel BM. 2013. “β-Lactamase-Producing Multidrug-Resistant Bacterial Pathogens from Tracheal Aspirates of Intensive Care Unit Patients at National Institute of Neurological and Allied Sciences, Nepal.” ISRN Microbiol. 2.
Ling ML, Tee YM, Tan SG, Amin IM, How KB, Tan KY and Lee LC. 2015. “Risk Factors for Acquisition of Carbapenem Resistant Enterobacteriaceae in an Acute Tertiary Care Hospital in Singapore.” Antimicrobial Resistance and Infection Control. 4 (26): 1–7. doi:10.1186/s13756-015-0066-3.
Mahon C, Manuselis G and Lehman D. 2010. Textbook of Diagnostic Microbiology. 2 edition. Saunders/Elsevier.
Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ and Whichard JM. 2003. “Imipenem Resistance in a Salmonella Clinical Strain Due to Plasmid-Mediated Class A Carbapenemase KPC-2.” Antimicrob Agents Chemother. 47 (4): 1297–1300.
Morfin-Otero R, Tinoco-Favila JC, Sader HS, Salcido-Gutierrez L, Perez-Gomez HR, Gonzalez-Diaz E, Petersen L and Rodriguez-Noriega E. 2012. “Resistance Trends in Gram-Negative Bacteria. Surveillance Results from Two Mexican Hospitals, 2005–2010.” BMC Research Notes. 5: 277.
Munoz-prince LS and Quinn JP. 2009. “The Spread of Klebsiella Pneumoniae Carbapenemases: A Tale of Strains, Plasmids, and Transposons.” Clin Infect Dis. 49: 1739–41.
Murray PR, Rosenthal KS and Pfaller M. 2009. Medical Microbiology. 6 edition. Mosby.
Mushtaq S, Ge Y and Livermore DM. 2004. “Comparative Activities of Doripenem versus Isolates, Mutants, and Transconjugants of Enterobacteriaceae and Acinetobacter Spp. with Characterized β-Lactamases.” Antimicrob. Agents Chemother. 48 (4): 1313–19.
Nair PK and Vaz MS. 2013. “Prevalence of Carbapenem Resistant Enterobacteriaceae from Tertiary Care Hospital in Mumbai, India.” J Microbiol Infect Dis. 3 (4): 207–10.
Nordmann P, Naas T and Poirel L. 2011. “Global Spread of Carbapenemase-Producing Enterobacteriaceae.” Emerg Infect Dis. 17 (10): 1791–98.
Parimala TV. 2017. “Screening of Carbapenem Resistant Enterobacteriaceae among Nosocomial Isolates: A Study from South India.” Int J Curr Microbiol App Sci. 6 (4): 460–65.
Bassetti M, Nicolini L, Esposito S, Righi E, Viscoli C. 2009. “Current Status of Newer Carbapenems.” Current Medicinal Chemistry 16 (5): 564–75.
Bhandari P, Thapa G, Pokhrel BM, Bhatta DR and Devkota U. 2015. “Nosocomial Isolates and Their Drug Resistant Pattern in ICU Patients at National Institute of Neurological and Allied Sciences, Nepal.” Int J Microbiol. doi:10.1155/2015/572163.
Bora A, Sanjana R, Jha BK, Mahaseth SN and Pokharel K. 2014. “Incidence of Metallo-Beta Lactamase Producing Clinical Isolates of Escherichia Coli and Klebsiella Pneumoniae in Central Nepal.” BMC Res Notes 7: 557.
Bratu S, Brooks S, Burney S, Kochar S, Gupta J, Landman D and Quale J. 2007. “Detection and Spread of Escherichia Coli Possessing the Plasmid-Borne Carbapenemase KPC-2 in Brooklyn, New York.” Clin Infect Dis. 44 (7): 972–75.
Bratu S, Landman D, Alam M, Tolentino E and Quale J. 2005. “Detection of KPC Carbapenem-Hydrolyzing Enzymes in Enterobacter Spp. from Brooklyn, New York.” Antimicrob Agents Chemother. 49 (2): 776–778. doi:10.1128/AAC.49.2.776-778.2005.
Brennan BM, Coyle JR, Marchaim D, Pogue JM, Boehme M, Finks J and Malani AN, et al. 2014. “Statewide Surveillance of Carbapenem-Resistant Enterobacteriaceae in Michigan.” Infect Control Hosp Epidemiol. 35 (4): 342–49.
Brenner DJ, Krieg NR, Staley JT, Garrity GM, Boone DR, Vos PD, Goodfellow M, Rainey FA and Schleifer KH. 2005. “The Proteobacteria, Part B. The Gammaproteobacteria.” In Bergey’s Manual of Systematic Bacteriology, 1203. Springer US. doi:https://doi.org/10.1007/0-387-28022-7.
Brink A, Coetzee J, Clay C, Corcoran C, van Greune J, Deetlefs JD, Nutt L, Feldman C, Richards G, Nordmann P and Poirel L. 2012. “The Spread of Carbapenem-Resistant Enterobacteriaceae in South Africa: Risk Factors for Acquisition and Prevention.” S Afr Med J. 102 (7): 599–601.
Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen Ø, Seifert H, Woodford N and Nordmann P. 2012.
“European Network on Carbapenemases: Rapid Evolution and Spread of Carbapenemases among Enterobacteriaceae in Europe.” Clin Microbiol Infect. 18 (5): 413–31.
CDC. 2009. “Centers for Diseases Control and Prevention. Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing Enterobacteriaceae in Acute Care Facilities.” MMWR Morb Mortal Wkly Rep. 58 (10): 256–60.
CDC. 2013. “Centers for Disease Control and Prevention: Vital Signs: Carbapenem-Resistant Enterobacteriaceae.” MMWR 62 (9): 165–70.
CLSI. 2011. “Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing. Twenty-First Informational Supplement. M100-S16 Wayne, PA” 31 (1): 1–165.
Cornaglia G, Guan L, Fontana R and Satta G. 1992. “Diffusion of Meropenem and Imipenem through the Outer Membrane of Escherichia Coli K-12 and Correlation with Their Antibacterial Activities.” Antimicrob Agents Chemother. 36 (9): 1902–8.
Forbes BA, Sahm DF and Weissfeld AS. 2007. Bailey and Scott’s Diagnostic Microbiology. 12 edition. Mosby.
Gupta N, Limbago BM, Patel JB and Kallen AJ. 2011. “Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention.” Clin Infect Dis. 53 (1): 60–67.
Hawkey PM. 2008. “The Growing Burden of Antimicrobial Resistance.” J Antimicrob Chemother. 62 (1): 1–9.
Jacoby GA, Mills DM and Chow N. 2004. “Role of Beta-Lactamases and Porins in Resistance to Ertapenem and Other Betalactams in Klebsiella Pneumoniae.” Antimicrob Agents Chemother. 48: 3203–6.
Jacoby JT, Klein GE, Laxminarayan R, Beldavs Z, Lynfield R, Kallen AJ and Ricks P, et al. 2013. “Vital Signs: Carbapenem-Resistant Enterobacteriaceae.” MMWR 62 (9): 165–69.
Karn S, Pant ND, Neupane S, Khatiwada S, Basnyat S and Shrestha B. 2016. “Prevalence of Carbapenem Resistant Bacterial Strains Isolated from Different Clinical Samples: Study from a Tertiary Care Hospital in Kathmandu, Nepal.” Journal of Biomedical Sciences 3 (1): 11–15.
Khanal S, Joshi DR, Bhatta DR, Devkota U and Pokhrel BM. 2013. “β-Lactamase-Producing Multidrug-Resistant Bacterial Pathogens from Tracheal Aspirates of Intensive Care Unit Patients at National Institute of Neurological and Allied Sciences, Nepal.” ISRN Microbiol. 2.
Ling ML, Tee YM, Tan SG, Amin IM, How KB, Tan KY and Lee LC. 2015. “Risk Factors for Acquisition of Carbapenem Resistant Enterobacteriaceae in an Acute Tertiary Care Hospital in Singapore.” Antimicrobial Resistance and Infection Control. 4 (26): 1–7. doi:10.1186/s13756-015-0066-3.
Mahon C, Manuselis G and Lehman D. 2010. Textbook of Diagnostic Microbiology. 2 edition. Saunders/Elsevier.
Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ and Whichard JM. 2003. “Imipenem Resistance in a Salmonella Clinical Strain Due to Plasmid-Mediated Class A Carbapenemase KPC-2.” Antimicrob Agents Chemother. 47 (4): 1297–1300.
Morfin-Otero R, Tinoco-Favila JC, Sader HS, Salcido-Gutierrez L, Perez-Gomez HR, Gonzalez-Diaz E, Petersen L and Rodriguez-Noriega E. 2012. “Resistance Trends in Gram-Negative Bacteria. Surveillance Results from Two Mexican Hospitals, 2005–2010.” BMC Research Notes. 5: 277.
Munoz-prince LS and Quinn JP. 2009. “The Spread of Klebsiella Pneumoniae Carbapenemases: A Tale of Strains, Plasmids, and Transposons.” Clin Infect Dis. 49: 1739–41.
Murray PR, Rosenthal KS and Pfaller M. 2009. Medical Microbiology. 6 edition. Mosby.
Mushtaq S, Ge Y and Livermore DM. 2004. “Comparative Activities of Doripenem versus Isolates, Mutants, and Transconjugants of Enterobacteriaceae and Acinetobacter Spp. with Characterized β-Lactamases.” Antimicrob. Agents Chemother. 48 (4): 1313–19.
Nair PK and Vaz MS. 2013. “Prevalence of Carbapenem Resistant Enterobacteriaceae from Tertiary Care Hospital in Mumbai, India.” J Microbiol Infect Dis. 3 (4): 207–10.
Nordmann P, Naas T and Poirel L. 2011. “Global Spread of Carbapenemase-Producing Enterobacteriaceae.” Emerg Infect Dis. 17 (10): 1791–98.
Parimala TV. 2017. “Screening of Carbapenem Resistant Enterobacteriaceae among Nosocomial Isolates: A Study from South India.” Int J Curr Microbiol App Sci. 6 (4): 460–65.
Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB and Bonomo RA. 2003.
“Extended-Spectrum Beta-Lactamases in Klebsiella Pneumoniae Bloodstream Isolates from Seven Countries: Dominance and Widespread Prevalence of SHV- and CTXM-Type Beta-Lactamases.” Antimicrob Agents Chemother. 47 (11): 3554–60.
Peleg AY and Hooper DC. 2010. “Hospital-Acquired Infections Due to Gram-Negative Bacteria.” N Engl J Med. 362 (19): 1804–13.
Philippon A, Arlet G and Jacoby GA. 2002. “Plasmid-Determined AmpC-Type Beta-Lactamases.” Antimicrob Agents Chemother. 46 (1): 1–11.
Poirel L, Héritier C, Spicq C and Nordmann P. 2004. “In Vivo Acquisition of High-Level Resistance to Imipenem in Escherichia Coli.” J Clin Microbiol. 42 (8): 3831–33.
Prakash D and Saxena RS. 2013. “Distribution and Antimicrobial Susceptibility Pattern of Bacterial Pathogens Causing Urinary Tract Infections in Urban Community of Meerut City, India.” ISRN Microbiology. doi:10.1155/2013/749629.
Queenan AM and Bush K. 2007. “Carbapenemases: The Versatile Beta-Lactamases.” Clin Microbial Rev. 20 (3): 440–58.
Saurina G, Quale JM, Manikal VM, Oydna E and Landman D. 2000. “Antimicrobial Resistance in Enterobacteriaceae in Brooklyn, NY: Epidemiology and Relation to Antibiotic Usage Patterns.” Journal of Antimicrobial Chemotherapy 45 (6): 895–98.
Shahid M, Sobia UF, Singh A, Khan HM, Malik A and Shukla I. 2012. “Molecular Epidemiology of Carbapenem Resistant Enterobacteriaceae from a North India Tertiary Hospital.” N Z J Med Lab Sci. 66: 5–7.
Tsakris A, Themeli-Digalaki K, Poulou A, Vrioni G, and Koumaki V et al. Voulgari E. 2011. “Comparative Evaluation of Combined_disk Tests Using Different Boronic Acid Compounds for Detection of Klebsiella Pneumoniae Carbapenemase Producing Enterobacteriaceae Clinical Isolates.” J Clin Microbiol. 49 (8): 2804–9.
Villegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M and Quinn JP. 2006. “First Detection of the Plasmid-Mediated Class A Carbapenemase KPC-2 in Clinical Isolates of Klebsiella Pneumoniae from South America.” Antimicrob Agents Chemother. 50 (8): 2880–82. doi:10.1128/AAC.00186-06.
Walsh TR. 2005. “The Emergence and Implications of Metallo-β-Lactamases in Gram-Negative Bacteria.” Clin. Microbiol. Infect. 11: 2–9.
Walsh TR et al. 2005. “Metallo-Βlactamases: The Quiet before the Storm??:” Clin. Microbiol. Rev. 18: 306–25.
Zaidah AR, Mohammad NI, Suraiya S and Harun A. 2017. “High Burden of Carbapenem-Resistant Enterobacteriaceae (CRE) Fecal Carriage at a Teaching Hospital: Cost-Effectiveness of Screening in Low-Resource Setting.” Antimicrobial Resistance and Infection Control. 6 (42). doi:10.1186/s13756-017-0200-5.
Zhu D, Zhang Y, Wang F and Chin J. 2006. “Surveillance of Bacterial Resistance in Shanghai Hospitals during 2006.” Chin J Infect Chemother. 7: 393–399.
Zhu D, Zhang Y and Wang F. 2007. “Surveillance of Bacterial Resistance from Hospitals in Shanghai in 2007.” Chin J Infect Chemother. 8: 401–410.

How to cite this article

Sanjib Adhikari, Sujan Khadka, Jid Chani Rana, Sushmita Baniya, Susma Poudel, Archana Chapagain and Ramesh Regmi, 2019. Prevalence of β-Lactamase Producing Carbapenem-Resistant Enterobacteriaceae among the Patients Attending Bharatpur Hospital. Bioscience Discovery, 10(2):64-71.

Note: The editor, owner, printer and publisher does not accept any responsibility regarding unsolicited publication material, authenticity of data, statement, inaccurate data, opinions, results and view expressed by the authors in articles are of their own and not of Bioscience Discovery Journal.
Online available on

http://www.jbsd.in
http://www.biosciencediscovery.com

Publisher: RUT Printer and Publisher, Jalna (MS) India